Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature

Abstract

The urgency of the problem of treating patients with lung cancer is caused by a steady increase in the lung cancer incidence and lung cancer mortality rates in population. Most patients with NSCLC initially present with locally advanced or disseminated disease. Currently, simultaneous chemoradiation therapy (CRT) is the standard for the treatment of locally advanced NSCLC, which appears superior to the single chemotherapy or radiation therapy, while the overall survival (OS) rate remains not high enough. Therefore, the search for optimal combinations of chemotherapeutic drugs and radiation therapy (CRT), as well as fractionation regimens is a promising direction in the treatment of such patients. In this article, we will review the on-topic studies data that are currently available, future directions of the therapy and objectives.

Keywords

• chemoradiation therapy
• lung cancer
• immunotherapy
• durvalumab